event-trade登录编辑
🏢 官网IRSDGRDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 20:30:00(美东 08:30)时区推断·⟳ 抓取 20:34:38回填·⚡ 决策 10-21 20:35:41·6.1 天前

Schrödinger(SDGR)公告将于11月4日盘后发布2026年三季度财报,纯日程通知无任何业绩数字

这是一份纯程序性的财报发布日期/电话会议日程公告,不含收入、利润、EPS、指引、订单或管线进展等任何增量事实,不构成方向性催化;应等待2026-11-04盘后实际财报再据surprise研判。

📄 原文SDGR↗ 原文
Schrödinger to Announce Third Quarter 2026 Financial Results on November 4
NEWS RELEASE Schrödinger to Announce Third Quarter 2026 Financial Results on November 4 2026-10-21 NEW YORK--(BUSINESS…
不做 Schrödinger, Inc.(SDGR.US)
纯财报发布日期/电话会议日程的程序性公告,无收入、利润、指引、订单等任何增量事实,方向中性、无预期差与edge;待2026-11-04盘后实际Q3财报发布后再据surprise独立研判
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Schrödinger仅预告11月4日盘后发财报并开电话会,全文无任何数字或指引,属中性日程通知,无预期差和交易edge,故不做。

🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 low ↗

主要风险

  • 本通知本身无风险;真正变量是11月4日实际财报,软件收入与合作/自研管线进展可能带来显著波动,届时需独立研判

先例如何影响了这次决策

对本次决策的影响:确认在财报实际发布前不下单,等待2026-11-04盘后真实数据

方向:无同类事件先例面板;纯财报日期预告为程序性公告,历史上不构成方向性催化,实际涨跌由财报日本身的surprise决定

涨幅量级:无高相似锚定先例可校准幅度,日期通知阶段不设tp/sl

形态:不适用

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
  1. search_processed_events 成功 stock_tools HTTP · 1,610 ms
    {"result": "search_processed_events:agent query=`schrodinger q3 2026 earnings date conference call webcast | schrödinger sdgr third quarter 2026 financial results november 4 announcement`;结构化索引覆盖完整 72 小时;旧记录兼容扫描近 72.0/72 小时、22767 条本臂决策(完整),返回 2 条候选。\n• 10-21 12:08 UTC(北京 20:08) [bm25:43%] 不做 BXC.US

原文全文

展开原文 · 1,341 字
NEWS RELEASE




Schrödinger to Announce Third Quarter 2026
Financial Results on November 4
2026-10-21

NEW YORK--(BUSINESS WIRE)-- Schrödinger, Inc. (Nasdaq: SDGR) will report its third quarter 2026 nancial results
on Wednesday, November 4, 2026, after the nancial markets close. The company will host a conference call and
webcast at 4:30 p.m. ET.

The live webcast can be accessed in the “Investors” section of Schrödinger’s website and will be archived for
approximately 90 days following the event.

About Schrödinger

Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of
novel, highly optimized molecules for drug development and materials design. Schrödinger’s software platform is
built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial
companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a
portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com, follow us on
LinkedIn, or visit our blog, Extrapolations.com.

Matthew Luchini
Schrödinger, Inc.
matthew.luchini@schrodinger.com
917-719-0636

Source: Schrödinger


1

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

  1. 5ac77ed985 · 2026-10-21 20:35 · doubao / doubao-seed-evolving-latest-version · 策略包 658c0c1e2ba5当前